Clinical Programs

Our Clinical Programs
NanOlogy, together with affiliate Soria, have launched a broad clinical program to evaluate local delivery of sterile and topical forms of our patented submicron particle production technology platform. Developed under FDA’s streamlined 505(b)2 regulatory pathway, the program includes six clinical trials currently enrolling patients.  In 2018 NanOlogy expects to begin clinical trials on NanoDoce® (sterile nanoparticle docetaxel) pending IND approval. Current clinical trials are listed below with links to their clinical overviews in: clinicaltrials.gov.

Current Clinical Trials of NanoPac® (sterile nanoparticle paclitaxel) for Suspension

Phase 2 Trial
of intraperitoneal NanoPac in subjects with Ovarian Cancer.
Phase 2 Trial
of intratumorally-injected NanoPac in subjects with prostate cancer scheduled for prostatectomy.
Phase 2 Trial
of NanoPac to treat subjects with pancreatic adenocarcinoma located in the tail or body of the pancreas via direct intratumoral injection.
Phase 2 Trial
trial to evaluate NanoPac administered intracystically via endoscopic ultrasound-guided fine needle injection (EUS-FNI) in subjects with mucinous cystic pancreatic neoplasms.

Current Clinical Trials of SOR007 (nanoparticle paclitaxel) Ointment

Phase 2 Trial
open-label, dose-rising study evaluating SOR007 (uncoated nanoparticle paclitaxel) Ointment for the treatment of cutaneous metastases from non-melanoma cancer.
Phase 2 Trial
randomized, double-blind, dose rising study to determine the safety, tolerability, and preliminary efficacy of SOR007 (uncoated nanoparticle paclitaxel) Ointment compared to ointment vehicle applied to actinic keratosis (AK) lesions. (Under NanOlogy affiliate, Soria.)

(817) 900-4002
3909 Hulen Street
Fort Worth, Texas 76107